Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

Nora M. Navone, Wytske M. van Weerden, Robert L. Vessella, Elizabeth D. Williams, Yuzhuo Wang, John T. Isaacs, Holly M. Nguyen, Zoran Culig, Gabri van der Pluijm, Cyril A. Rentsch, Rute B. Marques, Corrina M.A. de Ridder, Lukas Bubendorf, George N. Thalmann, William Nathaniel Brennen, Frédéric R. Santer, Patrizia L. Moser, Peter Shepherd, Eleni Efstathiou, Hui XueDong Lin, Anne Collins, Norman Maitland, Mark Buzza, Michelle Kouspou, Ariel Achtman, Renea A. Taylor, Gail Risbridger, Eva Corey

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, the Movember Foundation launched a Global Action Plan 1 (GAP1) project to support an international collaborative prostate cancer PDX program involving eleven groups. Between these Movember consortium members, a total of 98 authenticated human prostate cancer PDXs were available for characterization. Eighty three of these were derived directly from patient material, and 15 were derived as variants of patient-derived material via serial passage in androgen deprived hosts. A major goal of the Movember GAP1 PDX project was to provide the prostate cancer research community with a summary of both the basic characteristics of the 98 available authenticated serially transplantable human prostate cancer PDX models and the appropriate contact information for collaborations. Herein, we report a summary of these PDX models. Methods: PDX models were established in immunocompromised mice via subcutaneous or subrenal-capsule implantation. Dual-label species (ie, human vs mouse) specific centromere and telomere Fluorescence In Situ Hybridization (FISH) and immuno-histochemical (IHC) staining of tissue microarrays (TMAs) containing replicates of the PDX models were used for characterization of expression of a number of phenotypic markers important for prostate cancer including AR (assessed by IHC and FISH), Ki67, vimentin, RB1, P-Akt, chromogranin A (CgA), p53, ERG, PTEN, PSMA, and epithelial cytokeratins. Results: Within this series of PDX models, the full spectrum of clinical disease stages is represented, including androgen-sensitive and castration-resistant primary and metastatic prostate adenocarcinomas as well as prostate carcinomas with neuroendocrine differentiation. The annotated clinical characteristics of these PDXs were correlated with their marker expression profile. Conclusion: Our results demonstrate the clinical relevance of this series of PDXs as a platform for both basic science studies and therapeutic discovery/drug development. The present report provides the prostate cancer community with a summary of the basic characteristics and a contact information for collaborations using these models.

Original languageEnglish
Pages (from-to)1262-1282
Number of pages21
JournalProstate
Volume78
Issue number16
DOIs
Publication statusPublished - 1 Dec 2018

Keywords

  • patient-derived xenograft
  • PDX
  • prostate cancer

Cite this

Navone, N. M., van Weerden, W. M., Vessella, R. L., Williams, E. D., Wang, Y., Isaacs, J. T., ... Corey, E. (2018). Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate, 78(16), 1262-1282. https://doi.org/10.1002/pros.23701
Navone, Nora M. ; van Weerden, Wytske M. ; Vessella, Robert L. ; Williams, Elizabeth D. ; Wang, Yuzhuo ; Isaacs, John T. ; Nguyen, Holly M. ; Culig, Zoran ; van der Pluijm, Gabri ; Rentsch, Cyril A. ; Marques, Rute B. ; de Ridder, Corrina M.A. ; Bubendorf, Lukas ; Thalmann, George N. ; Brennen, William Nathaniel ; Santer, Frédéric R. ; Moser, Patrizia L. ; Shepherd, Peter ; Efstathiou, Eleni ; Xue, Hui ; Lin, Dong ; Collins, Anne ; Maitland, Norman ; Buzza, Mark ; Kouspou, Michelle ; Achtman, Ariel ; Taylor, Renea A. ; Risbridger, Gail ; Corey, Eva. / Movember GAP1 PDX project : An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. In: Prostate. 2018 ; Vol. 78, No. 16. pp. 1262-1282.
@article{1053b766ac494a2096525d5a56c69256,
title = "Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models",
abstract = "Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40{\%} and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, the Movember Foundation launched a Global Action Plan 1 (GAP1) project to support an international collaborative prostate cancer PDX program involving eleven groups. Between these Movember consortium members, a total of 98 authenticated human prostate cancer PDXs were available for characterization. Eighty three of these were derived directly from patient material, and 15 were derived as variants of patient-derived material via serial passage in androgen deprived hosts. A major goal of the Movember GAP1 PDX project was to provide the prostate cancer research community with a summary of both the basic characteristics of the 98 available authenticated serially transplantable human prostate cancer PDX models and the appropriate contact information for collaborations. Herein, we report a summary of these PDX models. Methods: PDX models were established in immunocompromised mice via subcutaneous or subrenal-capsule implantation. Dual-label species (ie, human vs mouse) specific centromere and telomere Fluorescence In Situ Hybridization (FISH) and immuno-histochemical (IHC) staining of tissue microarrays (TMAs) containing replicates of the PDX models were used for characterization of expression of a number of phenotypic markers important for prostate cancer including AR (assessed by IHC and FISH), Ki67, vimentin, RB1, P-Akt, chromogranin A (CgA), p53, ERG, PTEN, PSMA, and epithelial cytokeratins. Results: Within this series of PDX models, the full spectrum of clinical disease stages is represented, including androgen-sensitive and castration-resistant primary and metastatic prostate adenocarcinomas as well as prostate carcinomas with neuroendocrine differentiation. The annotated clinical characteristics of these PDXs were correlated with their marker expression profile. Conclusion: Our results demonstrate the clinical relevance of this series of PDXs as a platform for both basic science studies and therapeutic discovery/drug development. The present report provides the prostate cancer community with a summary of the basic characteristics and a contact information for collaborations using these models.",
keywords = "patient-derived xenograft, PDX, prostate cancer",
author = "Navone, {Nora M.} and {van Weerden}, {Wytske M.} and Vessella, {Robert L.} and Williams, {Elizabeth D.} and Yuzhuo Wang and Isaacs, {John T.} and Nguyen, {Holly M.} and Zoran Culig and {van der Pluijm}, Gabri and Rentsch, {Cyril A.} and Marques, {Rute B.} and {de Ridder}, {Corrina M.A.} and Lukas Bubendorf and Thalmann, {George N.} and Brennen, {William Nathaniel} and Santer, {Fr{\'e}d{\'e}ric R.} and Moser, {Patrizia L.} and Peter Shepherd and Eleni Efstathiou and Hui Xue and Dong Lin and Anne Collins and Norman Maitland and Mark Buzza and Michelle Kouspou and Ariel Achtman and Taylor, {Renea A.} and Gail Risbridger and Eva Corey",
year = "2018",
month = "12",
day = "1",
doi = "10.1002/pros.23701",
language = "English",
volume = "78",
pages = "1262--1282",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Blackwell",
number = "16",

}

Navone, NM, van Weerden, WM, Vessella, RL, Williams, ED, Wang, Y, Isaacs, JT, Nguyen, HM, Culig, Z, van der Pluijm, G, Rentsch, CA, Marques, RB, de Ridder, CMA, Bubendorf, L, Thalmann, GN, Brennen, WN, Santer, FR, Moser, PL, Shepherd, P, Efstathiou, E, Xue, H, Lin, D, Collins, A, Maitland, N, Buzza, M, Kouspou, M, Achtman, A, Taylor, RA, Risbridger, G & Corey, E 2018, 'Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models', Prostate, vol. 78, no. 16, pp. 1262-1282. https://doi.org/10.1002/pros.23701

Movember GAP1 PDX project : An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. / Navone, Nora M.; van Weerden, Wytske M.; Vessella, Robert L.; Williams, Elizabeth D.; Wang, Yuzhuo; Isaacs, John T.; Nguyen, Holly M.; Culig, Zoran; van der Pluijm, Gabri; Rentsch, Cyril A.; Marques, Rute B.; de Ridder, Corrina M.A.; Bubendorf, Lukas; Thalmann, George N.; Brennen, William Nathaniel; Santer, Frédéric R.; Moser, Patrizia L.; Shepherd, Peter; Efstathiou, Eleni; Xue, Hui; Lin, Dong; Collins, Anne; Maitland, Norman; Buzza, Mark; Kouspou, Michelle; Achtman, Ariel; Taylor, Renea A.; Risbridger, Gail; Corey, Eva.

In: Prostate, Vol. 78, No. 16, 01.12.2018, p. 1262-1282.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Movember GAP1 PDX project

T2 - An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models

AU - Navone, Nora M.

AU - van Weerden, Wytske M.

AU - Vessella, Robert L.

AU - Williams, Elizabeth D.

AU - Wang, Yuzhuo

AU - Isaacs, John T.

AU - Nguyen, Holly M.

AU - Culig, Zoran

AU - van der Pluijm, Gabri

AU - Rentsch, Cyril A.

AU - Marques, Rute B.

AU - de Ridder, Corrina M.A.

AU - Bubendorf, Lukas

AU - Thalmann, George N.

AU - Brennen, William Nathaniel

AU - Santer, Frédéric R.

AU - Moser, Patrizia L.

AU - Shepherd, Peter

AU - Efstathiou, Eleni

AU - Xue, Hui

AU - Lin, Dong

AU - Collins, Anne

AU - Maitland, Norman

AU - Buzza, Mark

AU - Kouspou, Michelle

AU - Achtman, Ariel

AU - Taylor, Renea A.

AU - Risbridger, Gail

AU - Corey, Eva

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, the Movember Foundation launched a Global Action Plan 1 (GAP1) project to support an international collaborative prostate cancer PDX program involving eleven groups. Between these Movember consortium members, a total of 98 authenticated human prostate cancer PDXs were available for characterization. Eighty three of these were derived directly from patient material, and 15 were derived as variants of patient-derived material via serial passage in androgen deprived hosts. A major goal of the Movember GAP1 PDX project was to provide the prostate cancer research community with a summary of both the basic characteristics of the 98 available authenticated serially transplantable human prostate cancer PDX models and the appropriate contact information for collaborations. Herein, we report a summary of these PDX models. Methods: PDX models were established in immunocompromised mice via subcutaneous or subrenal-capsule implantation. Dual-label species (ie, human vs mouse) specific centromere and telomere Fluorescence In Situ Hybridization (FISH) and immuno-histochemical (IHC) staining of tissue microarrays (TMAs) containing replicates of the PDX models were used for characterization of expression of a number of phenotypic markers important for prostate cancer including AR (assessed by IHC and FISH), Ki67, vimentin, RB1, P-Akt, chromogranin A (CgA), p53, ERG, PTEN, PSMA, and epithelial cytokeratins. Results: Within this series of PDX models, the full spectrum of clinical disease stages is represented, including androgen-sensitive and castration-resistant primary and metastatic prostate adenocarcinomas as well as prostate carcinomas with neuroendocrine differentiation. The annotated clinical characteristics of these PDXs were correlated with their marker expression profile. Conclusion: Our results demonstrate the clinical relevance of this series of PDXs as a platform for both basic science studies and therapeutic discovery/drug development. The present report provides the prostate cancer community with a summary of the basic characteristics and a contact information for collaborations using these models.

AB - Background: While it has been challenging to establish prostate cancer patient-derived xenografts (PDXs), with a take rate of 10-40% and long latency time, multiple groups throughout the world have developed methods for the successful establishment of serially transplantable human prostate cancer PDXs using a variety of immune deficient mice. In 2014, the Movember Foundation launched a Global Action Plan 1 (GAP1) project to support an international collaborative prostate cancer PDX program involving eleven groups. Between these Movember consortium members, a total of 98 authenticated human prostate cancer PDXs were available for characterization. Eighty three of these were derived directly from patient material, and 15 were derived as variants of patient-derived material via serial passage in androgen deprived hosts. A major goal of the Movember GAP1 PDX project was to provide the prostate cancer research community with a summary of both the basic characteristics of the 98 available authenticated serially transplantable human prostate cancer PDX models and the appropriate contact information for collaborations. Herein, we report a summary of these PDX models. Methods: PDX models were established in immunocompromised mice via subcutaneous or subrenal-capsule implantation. Dual-label species (ie, human vs mouse) specific centromere and telomere Fluorescence In Situ Hybridization (FISH) and immuno-histochemical (IHC) staining of tissue microarrays (TMAs) containing replicates of the PDX models were used for characterization of expression of a number of phenotypic markers important for prostate cancer including AR (assessed by IHC and FISH), Ki67, vimentin, RB1, P-Akt, chromogranin A (CgA), p53, ERG, PTEN, PSMA, and epithelial cytokeratins. Results: Within this series of PDX models, the full spectrum of clinical disease stages is represented, including androgen-sensitive and castration-resistant primary and metastatic prostate adenocarcinomas as well as prostate carcinomas with neuroendocrine differentiation. The annotated clinical characteristics of these PDXs were correlated with their marker expression profile. Conclusion: Our results demonstrate the clinical relevance of this series of PDXs as a platform for both basic science studies and therapeutic discovery/drug development. The present report provides the prostate cancer community with a summary of the basic characteristics and a contact information for collaborations using these models.

KW - patient-derived xenograft

KW - PDX

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85052433082&partnerID=8YFLogxK

U2 - 10.1002/pros.23701

DO - 10.1002/pros.23701

M3 - Article

AN - SCOPUS:85052433082

VL - 78

SP - 1262

EP - 1282

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 16

ER -